NCT06618313 One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
| NCT ID | NCT06618313 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing GoBroad Hospital |
| Condition | B-Cell Non-Hodgkin Lymphoma-Recurrent |
| Study Type | INTERVENTIONAL |
| Enrollment | 8 participants |
| Start Date | 2025-03-27 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 8 participants in total. It began in 2025-03-27 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluate the Safety and Efficacy of JCXH-213 in Patients with Relapsed/Refractory B-cell non-Hodgkin Lymphoma
Eligibility Criteria
Inclusion Criteria: * Cytologically or histopathologically confirmed CD19-positive B-cell Hodgkin lymphoma according to WHO 2022 criteria, including but not limited to pathologically confirmed (1) diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS); (2) follicular lymphoma (FL); (3)histologically transformed into diffuse large B-cell lymphoma; (4) primary mediastinal large B-cell lymphoma (PMBCL); (5) High-grade B-cell lymphoma (HGBCL) etc. * ECOG performance status 0 to 1. * Existing measurable lesions (Lugano 2014 criteria, as detailed in Appendix 2), meeting one of the following conditions: 1) nodal lesions with a long axis length exceeding 15 mm (short axis length is measurable); 2) extra-nodal lesions with both long axis and short axis lengths exceeding 10 mm. Exclusion Criteria: * Patients with other malignant tumors within 5 years before screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local radical prostatectomy, radical ductal carcinoma in situ, and radical thyroidectomy. * B-cell non-Hodgkin lymphoma with active primary or secondary central nervous system involvement. * Life expectancy less than 3 months.
Contact & Investigator
Kai Hu, Chief Physician
PRINCIPAL INVESTIGATOR
Beijing GoBroad Hospital
Frequently Asked Questions
Who can join the NCT06618313 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying B-Cell Non-Hodgkin Lymphoma-Recurrent. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06618313 currently recruiting?
Yes, NCT06618313 is actively recruiting participants. Contact the research team at HK13610956245@163.com for enrollment information.
Where is the NCT06618313 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06618313 clinical trial?
NCT06618313 is sponsored by Beijing GoBroad Hospital. The principal investigator is Kai Hu, Chief Physician at Beijing GoBroad Hospital. The trial plans to enroll 8 participants.